OpportunityAnalyzer: Growth Hormone Deficiency – Opportunity Analysis and Forecasts to 2026

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Growth hormone deficiency (GHD) is a rare endocrine disorder characterized by inadequate secretion of growth hormone (GH) from the anterior pituitary gland. It is a heterogeneous disorder that may present in childhood (pediatric GHD) or later in adult life (adult GHD). Reduced GH secretion predominantly results in stunted linear growth in children; therefore, the standard-of-care GH replacement therapy serves to normalize height in children. Adults with GHD generally demonstrate biochemical abnormalities, which can also be successfully treated with recombinant GH. GlobalData estimates the 2016 sales for GHD at approximately $1.42 billion across the 7MM covered in this report. The market will grow moderately at a CAGR of 3.9% during the 10-year forecast period, generating sales of approximately $2.08 billion at the end of 2026. The US market is expected to grow the fastest of the three regions, recording a CAGR of 4.4% and generating around 69% of global sales in 2026. This growth will be driven primarily by the highly anticipated arrivals of the long-acting GHs and the resultant increase in compliance with and adherence to therapy. Although the more convenient long-acting GHs are expected to markedly change the GHD treatment landscape, and eventually replace daily GHs, market growth will be restricted by the continued negotiations between distributers and payers, which is expected to keep the prices of these new drugs at bay.
Key Questions Answered
Overall, the greatest unmet need in the GHD space is the issue with treatment adherence and compliance. There are other prominent unmet needs highlighted by the Key Opinion Leaders (KOLs). What are these? Will the pipeline drugs fulfil these unmet needs of the market?
The 10-year forecast period will mark the launch of four pipeline long-acting GH drugs. How will the sales of the existing drugs be impacted? Which of the pipeline drugs will have the highest peak sales at the highest CAGR, and why?
What are the roles of payers in this highly competitive disease space? How does this affect market shares of the GH brands? What are the chances of reimbursement for the long-acting GH drugs in pipeline?

Scope

Overview of GHD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Annualized GHD therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the GHD therapeutics market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global GHD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

Develop business strategies by understanding the trends shaping and driving the global GHD therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global GHD therapeutics market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the 7MM GHD therapeutics market from 2016-2026.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Novo Nordisk
Pfizer
Genentech/Roche
Ipsen SA
Eli Lilly
EMD Serono
Ferring
JCR Pharmaceuticals
Sandoz
LG Life Sciences
Biopartners GmbH
OPKO Health
Versartis Inc.
Ascendis Pharma
Genexine Inc.
Hanmi Pharmaceuticals
Aeterna Zentaris
Aileron Therapeutics
Critical Pharmaceuticals Limited
Emisphere Technologies Inc.

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Growth Hormone Deficiency: Executive Summary

2.1 GHD Market Will Exhibit Moderate Growth Between 2016 and 2026

2.2 Long-Acting Growth Hormones Will Fuel Market Growth and Improve the Treatment Landscape for GHD Patients

2.3 Payer Preferences Heavily Influence Market Shares of GH Drugs in the US

2.4 Disease Awareness and Stringent Regulatory and Insurance Policies Are Major Challenges in the GHD Market

2.5 Opportunities for New Entrants After the Launch of Long-Acting GHs Will Be Low During the Forecast Period

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Symptoms

4.3 Prognosis

4.4 Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 GHD in children

5.5 GHD in adults

5.6 Forecast Methodology

5.6.1 Sources

5.6.2 Forecast Assumptions and Methods

5.7 Epidemiological Forecast for GHD (2016-2026)

5.7.1 Diagnosed Prevalent Cases of GHD

5.7.2 Age-Specific Diagnosed Prevalent Cases of GHD

5.7.3 Sex-Specific Diagnosed Prevalent Cases of GHD

5.7.4 Idiopathic and Organic GHD in Children

5.7.5 Congenital and Acquired GHD Out of Organic GHD in Children

5.7.6 Idiopathic and Acquired GHD in Adults

5.7.7 Onset Timing

5.8 Discussion

5.8.1 Epidemiological Forecast Insight

5.8.2 Limitations of Analysis

5.8.3 Strengths of the Analysis

6 Current Treatment Options

6.1 Overview

6.2 Diagnosis and Treatment

6.2.1 Diagnosis

6.2.2 Treatment Guidelines and Leading Prescribed Drugs

6.3 Clinical Practice

6.4 Market Access and Reimbursement

6.5 Product Profiles – Recombinant Human Growth Hormones

6.5.1 Overview

6.5.2 Genotropin

6.5.3 Humatrope

6.5.4 Norditropin

6.5.5 Nutropin AQ

6.5.6 Saizen

6.5.7 Zomacton/Growject

6.5.8 Omnitrope

6.5.9 Valtropin Biosimilar

6.5.10 Efficacy

6.5.11 Safety

6.5.12 SWOT Analysis

6.6 Product Profiles – Long-Acting Recombinant Human Growth Hormones

6.6.1 Somatropin Biopartners (LB-03002)

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Improved Adherence to Therapy

7.2.1 Unmet Need

7.2.2 Gap Analysis

7.2.3 Opportunity

7.3 Disease Awareness and Physician Education

7.3.1 Unmet Need

7.3.2 Gap Analysis

7.3.3 Opportunity

7.4 Insurance Policies that Impact Patient Access

7.4.1 Unmet Need

7.4.2 Gap Analysis

7.4.3 Opportunity

7.5 Early Diagnosis

7.5.1 Unmet Need

7.5.2 Gap Analysis

7.5.3 Opportunity

7.6 Simpler and Safer Diagnostic Test

7.6.1 Unmet Need

7.6.2 Gap Analysis

7.6.3 Opportunity

7.7 Safer Treatment for Cancer Survivors

7.7.1 Unmet Need

7.7.2 Gap Analysis

7.7.3 Opportunity

7.8 Improved Way of Measuring Adherence

7.8.1 Unmet Need

7.8.2 Gap Analysis

7.8.3 Opportunity

8 R&D Strategies

8.1 Overview

8.1.1 Development of Long-Acting Growth Hormones

8.1.2 Novel Drug Delivery Strategies

8.1.3 Novel Diagnostic Methods

8.1.4 Adherence-Monitoring Electronic Devices

8.1.5 Licensing and Acquisitions

8.2 Clinical Trials Design

8.2.1 Current Clinical Trial Design

8.2.2 Future Clinical Trial Design

9 Pipeline Assessment

9.1 Overview

9.2 Somapacitan (NNC0195-0092)

9.2.1 Overview

9.2.2 Efficacy

9.2.3 Safety

9.2.4 SWOT Analysis

9.3 Lagova (MOD-4023)

9.3.1 Overview

9.3.2 Efficacy

9.3.3 Safety

9.3.4 SWOT Analysis

9.4 Somavaratan (VRS-317)

9.4.1 Overview

9.4.2 Efficacy

9.4.3 Safety

9.4.4 SWOT Analysis

9.5 TransCon Growth Hormone (ACP-001)

9.5.1 Overview

9.5.2 Efficacy

9.5.3 Safety

9.5.4 SWOT Analysis

9.6 Innovative Early-Stage Approaches

10 Pipeline Valuation Analysis

10.1 Clinical Benchmark of Key Pipeline Drugs

10.2 Commercial Benchmark of Key Pipeline Drugs

10.3 Competitive Assessment

10.4 Top-Line 10-Year Forecast

10.4.1 US

10.4.2 5EU

10.4.3 Japan

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.3.1 Forecasting Methodology

11.3.2 Diagnosed Patients

11.3.3 Percent Drug-Treated Patients

11.3.4 Drugs Included in Each Therapeutic Class

11.3.5 Launch and Patent Expiry Dates

11.3.6 General Pricing Assumptions

11.3.7 Individual Drug Assumptions

11.3.8 Pricing of Pipeline Agents

11.4 Primary Research – KOLs Interviewed for This Report

11.5 Payers Included in This Study

11.6 Primary Research – Prescriber Survey

11.7 About the Authors

11.7.1 Analyst

11.7.2 Therapy Area Director

11.7.3 Epidemiologist

11.7.4 Managing Epidemiologist

11.7.5 Global Director of Therapy Analysis and Epidemiology

11.7.6 Global Head of Healthcare

11.8 About GlobalData

11.9 Contact Us

11.10 Disclaimer

Table

Table 1: Growth Hormone Deficiency: Key Metrics in the 7MM

Table 2: Risk Factors and Comorbidities for GHD

Table 3: Diagnosed Prevalent Cases of GHD, Men and Women, All Ages, for 2016–2026.

Table 4: Treatment Guidelines for Growth Hormone Deficiency

Table 5: Approved Drugs for Growth Hormone Deficiency by Class in the Global Markets, 2016

Table 6: Product Profiles of Marketed Daily rGH Hormones for GHD Treatment

Table 7: SWOT Analysis of Marketed Recombinant Human Growth Hormones, 2017

Table 8: Product Profile – Somatropin Biopartners (LB-03002)

Table 9: Unmet Need and Opportunity in Growth Hormone Deficiency, 2017

Table 10: Examples of Pivotal Trials for Approved Treatments for Growth Hormone Deficiency

Table 11: Product Profile – Somapacitan (NNC0195-0092)

Table 12: Somapacitan SWOT Analysis, 2017

Table 13: Product Profile – Lagova (MOD-4023, hGH-CTP)

Table 14: Lagova SWOT Analysis, 2017

Table 15: Product Profile – Somavaratan (VRS-317)

Table 16: Somavaratan SWOT Analysis, 2017

Table 17: Product Profile – TransCon Growth Hormone (ACP-001)

Table 18: TransCon Growth Hormone SWOT Analysis, 2017

Table 19: Innovative Early-Stage Approaches for Growth Hormone Deficiency, 2017

Table 20: Clinical Benchmark of Key Pipeline Drugs – Growth Hormone Deficiency

Table 21: Commercial Benchmark of Key Pipeline Drugs – Growth Hormone Deficiency

Table 22: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care, Norditropin

Table 23: Key Events Impacting Sales for Growth Hormone Deficiency, 2016–2026

Table 24: Growth Hormone Deficiency Market – Global Drivers and Barriers, 2016–2026

Table 25: Key Historical and Projected Launch Dates for Growth Hormone Deficiency

Table 26: Key Historical and Projected Patent Expiry Dates for Growth Hormone Deficiency

Table 27: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for Growth Hormone Deficiency in 2016 and 2026

Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care, Norditropin

Figure 3: Overview of the GH/IGF-1 Pathway and Physiological Regulation of GH Secretion

Figure 4: GH/IGF-1 Axis and Actions in Bone, Muscle, and Body Metabolism

Figure 5: Age-Standardized Diagnosed Prevalence of GHD, Men and Women, All Ages, 2016

Figure 6: Case Flow Map of GHD

Figure 7: Sources Used and Not Used for the Diagnosed Prevalent Cases of GHD in Children

Figure 8: Sources Used and Not Used in the Forecast for Diagnosed Prevalent Cases of GHD in Adults

Figure 9 Sources Used and Not Used in the Forecast for Type of GHD in Children

Figure 10 Sources Used and Not Used in the Forecast for Type of GHD in Adults

Figure 11 Sources Used and Not Used in the Forecast for Onset Timing of GHD in Adults

Figure 12: Age-Specific Diagnosed Prevalent Cases of GHD, Men and Women, All Ages, 2016

Figure 13: Sex-Specific Diagnosed Prevalent Cases, Men, Women, All Ages, 2016

Figure 14: Diagnosed Prevalent Cases of GHD in Children Segmented into Idiopathic and Organic GHD, Boys and Girls, Ages ≤18 years, 2016.

Figure 15: Diagnosed Prevalent Cases of Congenital or Acquired GHD Out of Organic GHD, Boys and Girls, Ages ≤18 years, 2016

Figure 16: Idiopathic and Acquired GHD in Adults, Men and Women, Ages ≥19 Years, 2016.

Figure 17: Diagnosed Prevalent Cases by Onset Timing, Men and Women, Ages ≥19 Years, 2016.

Figure 18: Growth Hormone Deficiency Treatment Algorithm

Figure 19: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to be Licensed for Growth Hormone Deficiency in the 7MM During the Forecast Period

Figure 20: Global (7MM) Sales Forecast by Country for Growth Hormone Deficiency in 2016 and 2026

Figure 21: Global Sales Forecast by Drugs for Growth Hormone Deficiency, 2016 and 2026

Figure 22: Sales Forecast by Class for Growth Hormone Deficiency in the US, 2016 and 2026

Frequently asked questions

OpportunityAnalyzer: Growth Hormone Deficiency – Opportunity Analysis and Forecasts to 2026 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

OpportunityAnalyzer: Growth Hormone Deficiency – Opportunity Analysis and Forecasts to 2026 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at OpportunityAnalyzer: Growth Hormone Deficiency – Opportunity Analysis and Forecasts to 2026 in real time.

  • Access a live OpportunityAnalyzer: Growth Hormone Deficiency – Opportunity Analysis and Forecasts to 2026 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.